Related Experiment Videos
Bullous pemphigoid in two young infants
Danny Petronius1, Reuven Bergman
1Department of Dermatology and Pediatrics, Rambam Medical Center, Technion, Israel.
Pediatric Dermatology
|May 8, 2002
Insights
Bullous pemphigoid (BP) is rare in infants under 4 months. Two infants with BP required high-dose corticosteroids and dapsone for treatment, indicating a challenging disease course.
Area of Science:
- Pediatric Dermatology
- Autoimmune Blistering Diseases
Background:
- Bullous pemphigoid (BP) is a chronic autoimmune blistering disease typically affecting the elderly.
- Incidence in pediatric populations, especially infants, is exceptionally rare.
Observation:
- This report details two cases of bullous pemphigoid in infants aged 3 and 4 months.
- One infant presented with a severe, recalcitrant disease course.
Findings:
- The infant with a recalcitrant course demonstrated resistance to standard therapies.
- Treatment with a combination of high-dose oral corticosteroids and dapsone was ultimately effective.
Implications:
- These cases highlight the possibility of bullous pemphigoid in very young infants.
- Aggressive therapeutic strategies may be necessary for managing severe pediatric BP.
- Further research is warranted to understand the pathogenesis and optimal treatment of infantile bullous pemphigoid.
Abstract:
Bullous pemphigoid (BP) usually affects the elderly. The disease is uncommon in children and only a few cases have been described in infants < or =4 months of age. We describe two infants, ages 3 and 4 months, with BP. One infant had a recalcitrant course, and responded only to a combination of high-dose oral corticosteroids and dapsone.